Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

VYNE Therapeutics (VYNE) FCF Margin (2017 - 2025)

VYNE Therapeutics (VYNE) has disclosed FCF Margin for 9 consecutive years, with 11023.47% as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, FCF Margin fell 673963.0% year-over-year to 11023.47%, compared with a TTM value of 8141.41% through Dec 2025, down 138753.0%, and an annual FY2025 reading of 5811.23%, up 99296.0% over the prior year.
  • FCF Margin was 11023.47% for Q2 2025 at VYNE Therapeutics, down from 5673.76% in the prior quarter.
  • Across five years, FCF Margin topped out at 3669.6% in Q4 2021 and bottomed at 16589.66% in Q4 2022.
  • Average FCF Margin over 5 years is 7272.22%, with a median of 6100.77% recorded in 2022.
  • The sharpest move saw FCF Margin plummeted -1292006bps in 2022, then skyrocketed 983044bps in 2023.
  • Year by year, FCF Margin stood at 3669.6% in 2021, then plummeted by -352bps to 16589.66% in 2022, then soared by 59bps to 6759.21% in 2023, then plummeted by -58bps to 10713.1% in 2024, then dropped by -3bps to 11023.47% in 2025.
  • Business Quant data shows FCF Margin for VYNE at 11023.47% in Q2 2025, 5673.76% in Q1 2025, and 10713.1% in Q4 2024.